Purchasing oncology services: Summary recommendations

Cancer

Volumn 88, Issue 12, 2000, Pages 2876-2886

  Cangialose, Charles B ^a,b,o   Blair, Angela E ^c,d   Borchardt, Joan S ^a   Ades, Terri B ^e   Bennett, Charles L ^f   Dickersin, Kay ^g   Gesme Jr , Dean H ^h   Henderson, I Craig ⁱ   McGinnis Jr , LaMar S ^e   Mooney, K ^j   Mortenson, Lee E ^k   Sperduto, Paul ^l   Winkenwerder Jr , William ^m   Ballard, David J ⁿ  

^a Kerr L White Inst Hlth Serv Res   (United States)

^b VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^c GEORGIA STATE UNIVERSITY   (United States)

^d GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^e AMERICAN CANCER SOCIETY   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g BROWN UNIVERSITY   (United States)

^h Natl Coal for Cancer Survivorship   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF UTAH   (United States)

^k Assoc of Community Cancer Centers   (United States)

^l Methodist Hospital   (United States)

^m Blue Cross Blue Shield of Massachusetts   (United States)

ⁿ BAYLOR HEALTH CARE SYSTEM   (United States)

^o c/o Rebecca L Bagget MA ^*  (United States)

more..

Author keywords

Cancer care; Consensus development; Health care purchasing; Informed decision making; Oncology; Recommendations

Indexed keywords

ARTICLE; CANCER CENTER; CANCER PREVENTION; CANCER SCREENING; COST CONTROL; DECISION MAKING; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE DELIVERY; MANAGED CARE ORGANIZATION; PRIORITY JOURNAL; PURCHASING;

COSTS AND COST ANALYSIS; DECISION MAKING; DELIVERY OF HEALTH CARE; DELPHI TECHNIQUE; GROUP PURCHASING; GUIDELINES; HEALTH CARE COSTS; HEALTH CARE SECTOR; HEALTH CARE SURVEYS; HUMANS; MANAGED CARE PROGRAMS; MARKETING OF HEALTH SERVICES; MEDICAL ONCOLOGY;

EID: 0034659891     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000615)88:12<2876::AID-CNCR31>3.0.CO;2-M     Document Type: Article

References (52)

1. American Cancer Society. Cancer facts and figures 1997. Atlanta, GA: American Cancer Society, 1997.
2. Brown ML. The national economic burden of cancer: an update. J Natl Cancer Inst 1990;82:1811-4.
3. Schuette HL, Tucker TC, Brown ML, Potosky AL, Samuel T. The costs of cancer care in the United States: implications for action. Oncology 1995;9(Suppl 11):19-22.
4. Boyle P. Global burden of cancer. Lancet 1997;349(Suppl II):23-6.
5. Etheredge L, Jones SB, Lewin L. What is driving health system change? The new, fundamental forces for change as seen by health care leaders and market watchers. Health Aff 1996;15:93-101.
6. Kreiger, LM. New health care companies: putting physicians in control. JAMA 1977;278:1454-5.
7. Monaco GP, Goldschmidt P. What is proper care in the era of managed care? Oncology 1997;11:65-71.
8. Schauffler HH, Rodriguez T. Exercising purchasing power for preventive care. Health Aff 1996;15:73-85.
9. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996-3018.
10. Winn RJ, Botnick W, Dozier N. The NCCN guidelines development program. Oncology 1995;10(11 Suppl):23-8.
11. Healthy People 2000 Consortium. Healthy people 2000: national health promotion and disease prevention objectives. Washington, DC: U.S. Department of Health, 1990:416-40.
12. American Cancer Society National Conference on Cancer and the Changing Healthcare System. San Francisco, CA, May 3-5, 1990. Cancer 1991;67(Suppl 6):1715-823.
13. NCI Economics Conference. The integration of economic outcome measures into NCI sponsored therapeutic trials. J Natl Cancer Inst Monogr 1995;19:1-84.
14. Bennett CL, Westerman IL. Economic analysis during phase III clinical trials: who, what, when, where, and why? Oncology 1995;9(Suppl 11):169-75.
15. Outcomes Working Group, Health Services Research Committee, American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996;14:671-9.
16. Association of Community Cancer Center. Cancer treatments your insurance should cover: information for patients and their families. Rockville, MD: ACCC, 1995.
17. National Cancer Institute. Presidents Cancer Panel: fighting the war on cancer in an evolving health care system. Washington, DC: NIH-NCI Publication No. 661, 1997.
18. Eastman P. The new national cancer policy board gears up for action at first public forum. Oncol Times 1997;XIX: 19-30.
19. Kattlove H, Liberati A, Keeler E, Brook RH. Benefits and costs of screening and treatment for early breast cancer: development of a basic benefit package. JAMA 1995;273:142-8.
20. New B. The rationing debate. Defining a package of health-care services the NHS is responsible for: the case for. BMJ 1997;314:503-5.
21. Cancer Guidance Sub-Group of the Clinical Outcomes Group. Guidance for purchasers: improving outcomes in breast cancer. The Manual. NHS Executive; 1996:(Jul)3-9.
22. President's Cancer Panel Report. Cancer care issues in the United States: quality of care, quality of life. National Cancer Program. Washington, DC: National Cancer Institute, 1999: 1-28. Available from URL: http://deainfo.nic.nih.gov/ ADVISORY/pcp/pcp97-98rpt/pcp97-98rpt.htm.
23. Hewitt M, Simone JV, editors. Ensuring quality cancer care. Washington, DC: National Academy Press, 1999
24. Anonymous. American Cancer Society National Conference on Purchasing Oncology Services: current methods and models in the marketplace. September 11-12, 1997. Chicago, IL. Cancer 1998;82(Suppl 10):1989-2080.
25. Berelson B. Content analysis. In: Lindzey G, editor. Handbook of social psychology. Reading, MA: Addison Wesley, 1954:488-518.
26. Eddy DM. Benefit language: criteria that will improve quality while reducing costs. JAMA 1996;275:650-7.
27. Eddy DM. Investigational treatments: how strict should we be? JAMA 1997:278:179-85.
28. Young KE, Standards for cancer programs. Association of Community Cancer Centers, Rockville, MD, 1997.
29. Grilli R, Minozzi S, Tinazzi A, Labianca R, Sheldon TA, Liberati A. Do specialists do it better? The impact of specialization on the processes and outcomes of care for cancer patients [review]. Ann Oncol 1998;9:365-74.
30. Selby P, Gillis C, Haward R. Benefits from specialised cancer care. Lancet 1996;348:313-8.
31. Bailar JC, Gornik HL. Cancer undefeated. N Engl J Med 1997;336:169-74.
32. Kiefe CI, McKay SV, Halevy A, Brody BA. Is cost a barrier to screening mammography for low-income women receiving Medicare benefits? A randomized trial. Arch Intern Med 1994;154:1217-24.
33. Weinberg AD, Cooper HP, Lane M, Kripalani S. Screening behaviors and long-term compliance with mammography guidelines in a breast cancer screening program. Am J Prev Med 1997;13:29-35.
34. Bern L, Rennie D. The Cochrane collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA 1995;274:1935-8.
35. Hubbard SM, DeVita VT. PDQ: an innovation in information dissemination linking cancer research and clinical practice. Important Adv Oncol 1987;263-77.
36. Kennedy BJ. Reimbursement for patients enrolled in clinical trials. Cancer Invest 1994;12:249-56.
37. Sulmasy DP. Cancer, managed care, and therapeutic research: an ethicist's view. HMO Pract 1997;11:59-62.
38. Kaufman D. Cancer therapy and the randomized clinical trial: good medicine? Cancer 1993;73(9 Suppl):2801-4.
39. Lantos J. Ethics, randomization, and technology assessment. Cancer 1994;74(9 Suppl):2653-6.
40. Daugherty C, Ratain MJ, Grochowski E, Stocking C, Kodish E, Mick R, et al. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 1995;13: 162-72.
41. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin l, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996;276:637-49.
42. Weeks J. Measurement of utilities and quality-adjusted survival. Oncology 1995;9(Suppl 11):67-70.
43. Emanuel LL. A professional response to demands for accountability: practical recommendations regarding ethical aspects of patient care. Ann Intern Med 1996;124:240-9.
44. Mandelblatt JS, Ganz PA, Kahn KL.. Proposed agenda for the measurement of quality-of-care outcomes in oncology practice [review]. J Clin Oncol 1999;17:2614-22.
45. Crawshaw R, Rogers DE, Pellegrino ED, Bulger RJ, Lundberg GD, Bristow LR, et al. Patient physician covenant. JAMA 1995;273:1553.
46. Bethell C, Lansky D. Foundation for accountability: frame-work for accountability. In: Seltzer J, Nash D, editors. Models for measuring quality in managed care. New York: 1997, 55-7.
47. Austin DK. National coalition for cancer survivorship. Oncology 1996;10:120-7.
48. Cherny NI, Coyle N, Foley K. Guidelines in the care of the dying cancer patient. Hematol Oncol Clin North Am 1996; 10:261-87.
49. The GIVlO Investigators. Impact of follow-up testing on the survival and health-related quality of life in breast cancer patients. JAMA 1994;271:1587-92.
50. Del Turco MR, Domenico P, Angelo C, Ciatto S, Paolo P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial. JAMA 1994;271: 1593-7,
51. Virgo KS, Naunheim KS, McKirgan LW, Kissling ME, Lin JC, Johnson FE. Cost of patient follow-up after potentially cur-ative lung cancer treatment. J Thorac Cardiovasc Surg 1996; 112:356-63.
52. Gotzsche PC. Is there logic in the placebo? Lancet 1994;344: 925-6.